Isoda Wakana C, Segal Jack L
Research and Education Institute Summer Research Fellowship Program, Toyota Motor Corporation of America, Torrance, California, USA.
Pharmacotherapy. 2003 Feb;23(2):133-6. doi: 10.1592/phco.23.2.133.32089.
To determine the effects of 4-aminopyridine (4-AP) on heart rate and PR, QT, and QTc intervals in patients with longstanding spinal cord injury (SCI).
Randomized, active-treatment-controlled, dose level-blinded study, with allocation concealed.
University-affiliated, tertiary care medical center.
Sixty otherwise healthy male and female outpatients with traumatic SCI of more than 1 year's duration. Intervention. Oral administration and dose titration to tolerance of an immediate-release formulation of 4-AP.
The PR interval, heart rate, QT interval, and QTc interval obtained from standard 12-lead electrocardiograms (ECGs) at baseline (before administration of 4-AP) and after 1 month of treatment were compared. The QTc intervals were derived by using Bazett's formula (equation) incorporated into standard computerized analyses of 12-lead ECG printouts. The paired t test was performed to test for the significance of differences between means and variances. No statistically significant differences were noted in heart rate or between ECG time intervals measured at baseline and after 1 month of treatment with 4-AP among all patients with SCI or between subgroups stratified by injury level (tetraplegia, paraplegia) or sex.
During the 1-month period that 4-AP was administered, the heart rate and PR, QT, and QTc intervals all remained unchanged and stayed well within normal range in comparison to literature-derived control values. 4-Aminopyridine does not appear to influence the length of cardiac time intervals or heart rate and, hence, is unlikely to cause potentially life-threatening ventricular dysrrhythmias when administered long-term and taken orally in dosages of up to 30 mg/day. Specifically, cardiac repolarization (QTc interval) is unaffected in patients with SCI who continuously receive 4-AP for up to 1 month.
确定4-氨基吡啶(4-AP)对长期脊髓损伤(SCI)患者心率以及PR、QT和QTc间期的影响。
随机、活性治疗对照、剂量水平盲法研究,采用分配隐藏。
大学附属三级医疗中心。
60名年龄在1年以上的创伤性SCI门诊患者,男女不限,身体健康。干预措施:口服4-AP速释制剂并根据耐受情况进行剂量滴定。
比较基线(服用4-AP前)和治疗1个月后标准12导联心电图(ECG)测得的PR间期、心率、QT间期和QTc间期。QTc间期通过纳入标准计算机化12导联ECG打印输出分析中的Bazett公式(方程)得出。采用配对t检验来检验均值和方差之间差异的显著性。在所有SCI患者中,以及按损伤水平(四肢瘫、截瘫)或性别分层的亚组之间,服用4-AP 1个月后,心率或ECG时间间期在基线和治疗后测量值之间未发现统计学显著差异。
在服用4-AP的1个月期间,与文献得出的对照值相比,心率以及PR、QT和QTc间期均保持不变且处于正常范围内。4-氨基吡啶似乎不会影响心脏时间间期的长度或心率,因此,长期口服剂量高达30mg/天时,不太可能引起潜在危及生命的室性心律失常。具体而言,连续接受4-AP长达1个月的SCI患者的心脏复极化(QTc间期)未受影响。